U.S. pharma giant copyright scrapped two experimental weight loss products final calendar year—a as soon as-everyday capsule, lotiglipron, due to elevated liver enzymes in addition to a twice-everyday pill, danuglipron, due to solid Negative effects—but CEO Albert Bourla has explained the company is decided to “Perform and acquire” while in